Lyell Immunopharma logo

Lyell Immunopharma

LYEL | NASDAQ
Chart Builder DCF Calculator
$14.65
+$0.35 (+2.45%)
At close: Nov 16, 2026, 4:00 PM ET
$14.65
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
+2.45%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
26.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #874/1021 (Top 86%)

Key Statistics

Market Data

Market Cap $360.18M
1D Range
14.14 14.93
52W Range
7.51 38.60

Valuation (TTM)

PE -1.27
PB 1.87
EV/EBITDA -1.06

Valuation (NTM)

Forward PE N/A
Forward PEG 0.03
Price Target $39.50
Loading financial charts...

Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The com...

Sector Healthcare
Industry Biotechnology
Employees 161
IPO Date Jun 17, 2021
Fiscal Year January - December

Latest News

No news articles available yet.

Earnings

Latest Earnings
Nov 4, 2026
EPS
-$1.86
Beat +2.49%
REV
$3K
Beat +50.00%
Next Earnings
Mar 11, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Buy
Price Target
$39.50
Upside
+169.62%
Buy (3)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.